|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CNTN1 |
Gene summary for CNTN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CNTN1 | Gene ID | 1272 |
| Gene name | contactin 1 | |
| Gene Alias | F3 | |
| Cytomap | 12q12 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q12860 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1272 | CNTN1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.78e-12 | 7.55e-01 | -0.2116 |
| 1272 | CNTN1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 5.12e-03 | 6.63e-01 | -0.1941 |
| 1272 | CNTN1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 5.63e-05 | 6.19e-01 | -0.2107 |
| 1272 | CNTN1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 8.69e-11 | 7.87e-01 | -0.2119 |
| 1272 | CNTN1 | HTA12-15-2 | Human | Pancreas | PDAC | 4.41e-04 | 3.40e-01 | 0.2315 |
| 1272 | CNTN1 | HTA12-23-1 | Human | Pancreas | PDAC | 8.00e-12 | 8.99e-01 | 0.3405 |
| 1272 | CNTN1 | HTA12-25-1 | Human | Pancreas | PDAC | 2.04e-11 | 7.12e-01 | 0.313 |
| 1272 | CNTN1 | HTA12-26-1 | Human | Pancreas | PDAC | 5.25e-22 | 9.08e-01 | 0.3728 |
| 1272 | CNTN1 | HTA12-29-1 | Human | Pancreas | PDAC | 1.15e-54 | 1.13e+00 | 0.3722 |
| 1272 | CNTN1 | HTA12-30-1 | Human | Pancreas | PDAC | 1.14e-02 | 8.18e-01 | 0.3671 |
| 1272 | CNTN1 | HTA12-9-2 | Human | Pancreas | PDAC | 1.65e-02 | 2.54e-01 | 0.0835 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001097512 | Lung | AIS | regulation of neuron projection development | 69/1849 | 445/18723 | 1.05e-04 | 2.53e-03 | 69 |
| GO:003134612 | Lung | AIS | positive regulation of cell projection organization | 57/1849 | 353/18723 | 1.38e-04 | 3.05e-03 | 57 |
| GO:000202811 | Lung | AIS | regulation of sodium ion transport | 21/1849 | 90/18723 | 1.44e-04 | 3.13e-03 | 21 |
| GO:0018212 | Lung | AIS | peptidyl-tyrosine modification | 56/1849 | 378/18723 | 1.35e-03 | 1.68e-02 | 56 |
| GO:0018108 | Lung | AIS | peptidyl-tyrosine phosphorylation | 55/1849 | 375/18723 | 1.87e-03 | 2.08e-02 | 55 |
| GO:001095912 | Lung | AIS | regulation of metal ion transport | 58/1849 | 406/18723 | 2.63e-03 | 2.67e-02 | 58 |
| GO:00072193 | Lung | AIS | Notch signaling pathway | 29/1849 | 172/18723 | 2.93e-03 | 2.92e-02 | 29 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CNTN1 | NRCAM | CNTN1_NRCAM | CNTN | HNSCC | Precancer |
| CNTN1 | NRCAM | CNTN1_NRCAM | CNTN | Skin | AK |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CNTN1 | SNV | Missense_Mutation | c.712N>C | p.Lys238Gln | p.K238Q | Q12860 | protein_coding | deleterious(0.04) | benign(0.416) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CNTN1 | SNV | Missense_Mutation | c.2714N>T | p.Pro905Leu | p.P905L | Q12860 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| CNTN1 | SNV | Missense_Mutation | c.1490N>A | p.Gly497Glu | p.G497E | Q12860 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CNTN1 | SNV | Missense_Mutation | c.2882N>T | p.Ser961Phe | p.S961F | Q12860 | protein_coding | tolerated(0.71) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CNTN1 | SNV | Missense_Mutation | novel | c.1363N>T | p.Leu455Phe | p.L455F | Q12860 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CNTN1 | SNV | Missense_Mutation | rs556601462 | c.1514N>T | p.Thr505Met | p.T505M | Q12860 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| CNTN1 | SNV | Missense_Mutation | c.400N>A | p.Tyr134Asn | p.Y134N | Q12860 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-C8-A133-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CNTN1 | SNV | Missense_Mutation | c.2689G>C | p.Glu897Gln | p.E897Q | Q12860 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CNTN1 | SNV | Missense_Mutation | rs547467864 | c.2528G>A | p.Arg843Gln | p.R843Q | Q12860 | protein_coding | deleterious(0.02) | probably_damaging(0.978) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
| CNTN1 | SNV | Missense_Mutation | c.2689N>C | p.Glu897Gln | p.E897Q | Q12860 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |